$144.32 -0.67 (%) Biomarin Pharmaceutical Inc - NASDAQ

Jul. 27, 2015 | 04:00 PM

Partner Headlines

  1. BioMarin Gets Price Target Hike On Pipeline Strength

    IBD | Jul. 8, 2015 | 12:12PM EST
  2. 2 DMD drugs make progress

    IBD | Jun. 29, 2015 | 18:45PM EST
  3. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD | Jun. 29, 2015 | 10:18AM EST
  4. Baird Downgrades BioMarin Pharmaceutical To Neutral

    Benzinga | Jun. 19, 2015 | 10:31AM EST
  5. Benzinga's Volume Movers

    Benzinga | Jun. 19, 2015 | 10:31AM EST
  6. Benzinga's Top Downgrades

    Benzinga | Jun. 19, 2015 | 10:08AM EST
  7. Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following Announcement Of Positive BMN 111 Data; Jabil Circuit Shares Fall

    Benzinga | Jun. 18, 2015 | 15:32PM EST
  8. Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius Health Shares Surge

    Benzinga | Jun. 18, 2015 | 13:31PM EST
  9. BioMarin Stock Hits High On Dwarfism Drug Success

    IBD | Jun. 18, 2015 | 10:36AM EST
  10. Mid-Morning Market Update: Markets Open Higher; Kroger Earnings Beat Views

    Benzinga | Jun. 18, 2015 | 10:22AM EST
  11. Benzinga's Volume Movers

    Benzinga | Jun. 18, 2015 | 10:21AM EST
  12. Morning Market Gainers

    Benzinga | Jun. 18, 2015 | 09:39AM EST
  13. Dollar, Data Boost Stock Futures; Oracle Tumbles, Taser Gains

    IBD | Jun. 18, 2015 | 09:14AM EST
  14. Benzinga's Top #PreMarket Gainers

    Benzinga | Jun. 18, 2015 | 08:12AM EST
  15. BIOMARIN PHARMA

    IBD | Jun. 17, 2015 | 18:41PM EST
  16. Pier 1, BioMarin, HomeAway & Oracle Lead Wednesday's After-Hours Movers

    Benzinga | Jun. 17, 2015 | 17:39PM EST
  17. BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study

    Benzinga | Jun. 17, 2015 | 16:05PM EST
  18. BioMarin Submits Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

    Benzinga | Jun. 8, 2015 | 08:37AM EST
  19. Benzinga's Top Initiations

    Benzinga | Jun. 5, 2015 | 10:04AM EST
  20. Barclays Initiates BioMarin Pharmaceutical With Overweight

    Benzinga | Jun. 5, 2015 | 08:39AM EST
  21. Sarepta Soars On New Hope For Muscular-Dystrophy Drug

    IBD | May. 20, 2015 | 11:45AM EST
  22. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD | May. 6, 2015 | 18:20PM EST
  23. BIOMARIN PHARMA

    IBD | Apr. 30, 2015 | 18:40PM EST
  24. BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

    Benzinga | Apr. 27, 2015 | 09:44AM EST
  25. J.P. Morgan's 3 Biotechnology Picks

    GuruFocus | Apr. 14, 2015 | 21:01PM EST
  26. What Evercore Is Watching At BioMarin Pharmaceutical

    Benzinga | Feb. 25, 2015 | 17:17PM EST
  27. BioMarin To Report Revenue In-line With Consensus, Wedbush Says

    Benzinga | Feb. 20, 2015 | 17:03PM EST
  28. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD | Feb. 19, 2015 | 16:59PM EST
  29. Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval

    Benzinga | Feb. 17, 2015 | 13:54PM EST
  30. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD | Feb. 10, 2015 | 10:30AM EST
  31. BIOMARIN PHARMA

    IBD | Jan. 21, 2015 | 18:42PM EST
  32. State Of The Union Lights Up Biotech

    Benzinga | Jan. 21, 2015 | 06:25AM EST
  33. Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

    Benzinga | Jan. 16, 2015 | 15:34PM EST
  34. UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical On Positive Preliminary BMN-190 Data

    Benzinga | Jan. 14, 2015 | 07:08AM EST
  35. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  36. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD | Jan. 9, 2015 | 15:42PM EST
  37. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD | Jan. 8, 2015 | 08:02AM EST
  38. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of A Potential Sale

    Benzinga | Jan. 6, 2015 | 12:34PM EST
  39. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD | Dec. 23, 2014 | 16:11PM EST
  40. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical On Path To Long-Term Upside

    Benzinga | Dec. 11, 2014 | 10:04AM EST
  41. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB

    Benzinga | Dec. 10, 2014 | 08:05AM EST
  42. BioMarin Will Report Breadth of Innovative Development Pipeline at Analyst, Investor Day

    Benzinga | Dec. 9, 2014 | 08:05AM EST
  43. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga | Nov. 24, 2014 | 20:20PM EST
  44. BioMarin buying Prosensa

    IBD | Nov. 24, 2014 | 18:43PM EST
  45. Trio Of Major Deals Disclosed

    IBD | Nov. 24, 2014 | 18:42PM EST
  46. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly Results; Tetraphase Pharmaceuticals Shares Spike Higher

    Benzinga | Nov. 24, 2014 | 15:26PM EST
  47. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters Shares Jump On Acquisition News

    Benzinga | Nov. 24, 2014 | 13:55PM EST
  48. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire Prosensa For $17.75/Share

    Benzinga | Nov. 24, 2014 | 11:54AM EST
  49. Benzinga's Volume Movers

    Benzinga | Nov. 24, 2014 | 10:28AM EST
  50. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD | Nov. 24, 2014 | 10:22AM EST
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!